New French Transparency Regulations Ruled Valid by French Constitutional Court
- disclose fees above a certain threshold (to be established by the government) paid under agreements with HCPs and with other stakeholders;
- report the purpose of the agreements in a more detailed manner, and not by generic descriptions;
- "direct" and the "final" beneficiary of the agreements will have to be reported.
The specifics of these changes will be established by an upcoming implementing decree.
On 26 September 2016, a new EU-US collaboration between the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) was announced. This new collaboration is ...06 October 2016
On 1 September 2016, the European Medicines Agency ("EMA") opened for public consultation a Draft revision to its Guideline on the assessment of clinical safety and efficacy in the...08 September 2016